Allogene Therapeutics, Inc.
ALLO
$1.77
-$0.09-4.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -4.01% | 11.77% | |||
| Gross Profit | 18.50% | -11.77% | |||
| SG&A Expenses | 47.91% | 2.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.86% | 8.70% | |||
| Operating Income | -1.80% | -8.70% | |||
| Income Before Tax | -0.16% | -9.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.16% | -9.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.16% | -9.78% | |||
| EBIT | -1.80% | -8.70% | |||
| EBITDA | -2.43% | -9.85% | |||
| EPS Basic | 26.85% | -3.26% | |||
| Normalized Basic EPS | 26.81% | -3.26% | |||
| EPS Diluted | 26.85% | -3.26% | |||
| Normalized Diluted EPS | 26.81% | -3.26% | |||
| Average Basic Shares Outstanding | 36.89% | 6.31% | |||
| Average Diluted Shares Outstanding | 36.89% | 6.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||